Imgatuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Imgatuzumab
Accession Number
DB14884
Type
Biotech
Groups
Investigational
Description

Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer).

Synonyms
Not Available
External IDs
RO5083945
Categories
Not Available
UNII
V77J4WJF9Z
CAS number
959963-46-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Imgatuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentNeoplasms1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:32 / Updated on May 21, 2019 12:30